Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase

NCT01699217 · clinicaltrials.gov ↗

COMPLETED

Status

129

Enrollment

OTHER

Sponsor class

Conditions

Chronic Phase Philadelphia Positive
BCR-ABL Positive
Chronic Myeloid Leukaemia

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto